The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -66,489 |
| Depreciation and amortization | 276 |
| Share-based compensation | 8,368 |
| Amortization of premium and discount on marketable securities | -1,673 |
| Rou asset amortization | 1,196 |
| Prepaid expenses and other current assets | -5,116 |
| Accounts payable | -664 |
| Accrued expenses | 5,096 |
| Operating lease liability | -369 |
| Net cash used in operating activities | -49,143 |
| Purchases of marketable securities | 194,557 |
| Proceeds from sale or maturities of marketable securities | 101,276 |
| Purchase of property and equipment | 25 |
| Net cash (used in) provided by investing activities | -93,306 |
| Proceeds from issuance of common stock and warrants | 137,999 |
| Issuance costs from issuance of common stock | 8,638 |
| Proceeds from exercise of stock options | 1,275 |
| Taxes paid related to net shares settlement of rsus | 1,027 |
| Net cash provided by financing activities | 129,609 |
| Net change in cash, cash equivalents and restricted cash | -12,840 |
| Cash, cash equivalents and restricted cash at beginning of year | 44,051 |
| Cash, cash equivalents and restricted cash at end of period | 31,211 |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)